aluates Reports

$ 0.0

Automative

Global Non-oncology Biopharmaceuticals Market Research Report 2024

Published Date: March 2024

Report Code: QYRE-Auto-4J6201

Global Non oncology Biopharmaceuticals Market Insights Forecast to 2028

BUY CHAPTERS

Global Non-oncology Biopharmaceuticals Market Research Report 2024

Code: QYRE-Auto-4J6201

Report

March 2024

Pages:107

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Non-oncology Biopharmaceuticals Market Size

The global Non-oncology Biopharmaceuticals market was valued at US$ 295620 million in 2023 and is anticipated to reach US$ 531430 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.

Non-oncology Biopharmaceuticals Market

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.

North American market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Non-oncology Biopharmaceuticals in Immunology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Non-oncology Biopharmaceuticals include Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva and Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Non-oncology Biopharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-oncology Biopharmaceuticals.

Report Scope

The Non-oncology Biopharmaceuticals market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-oncology Biopharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-oncology Biopharmaceuticals companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Non-oncology Biopharmaceuticals Market Report

Report Metric	Details
Report Name	Non-oncology Biopharmaceuticals Market
Accounted market size in 2023	US$ 295620 million
Forecasted market size in 2030	US$ 531430 million
CAGR	8.3%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Biologics Biosimilars
Segment by Application	Immunology Endocrinology Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, UCB Pharma, Amgen, AbbVie, Takeda, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics, Swedish Orphan Biovitrum, Biogen
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-oncology Biopharmaceuticals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Non-oncology Biopharmaceuticals Market growing?

Ans: The Non-oncology Biopharmaceuticals Market witnessing a CAGR of 8.3% during the forecast period 2024-2030.

What is the Non-oncology Biopharmaceuticals Market size in 2030?

Ans: The Non-oncology Biopharmaceuticals Market size in 2030 will be US$ 531430 million.

Who are the main players in the Non-oncology Biopharmaceuticals Market report?

Ans: The main players in the Non-oncology Biopharmaceuticals Market are Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, UCB Pharma, Amgen, AbbVie, Takeda, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics, Swedish Orphan Biovitrum, Biogen

What are the Application segmentation covered in the Non-oncology Biopharmaceuticals Market report?

Ans: The Applications covered in the Non-oncology Biopharmaceuticals Market report are Immunology, Endocrinology, Others

What are the Type segmentation covered in the Non-oncology Biopharmaceuticals Market report?

Ans: The Types covered in the Non-oncology Biopharmaceuticals Market report are Biologics, Biosimilars

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Biologics

1.2.3 Biosimilars

1.3 Market by Application

1.3.1 Global Non-oncology Biopharmaceuticals Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Immunology

1.3.3 Endocrinology

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2019-2030)

2.2 Non-oncology Biopharmaceuticals Growth Trends by Region

2.2.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2019-2024)

2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030)

2.3 Non-oncology Biopharmaceuticals Market Dynamics

2.3.1 Non-oncology Biopharmaceuticals Industry Trends

2.3.2 Non-oncology Biopharmaceuticals Market Drivers

2.3.3 Non-oncology Biopharmaceuticals Market Challenges

2.3.4 Non-oncology Biopharmaceuticals Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue

3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2019-2024)

3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2019-2024)

3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue

3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio

3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2023

3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served

3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service

3.7 Date of Enter into Non-oncology Biopharmaceuticals Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Non-oncology Biopharmaceuticals Breakdown Data by Type

4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2019-2024)

4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030)

5 Non-oncology Biopharmaceuticals Breakdown Data by Application

5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2019-2024)

5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Non-oncology Biopharmaceuticals Market Size (2019-2030)

6.2 North America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)

6.4 North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Non-oncology Biopharmaceuticals Market Size (2019-2030)

7.2 Europe Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)

7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2019-2030)

8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2019-2024)

8.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2019-2030)

9.2 Latin America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)

9.4 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2019-2030)

10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)

10.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Detail

11.1.2 Roche Business Overview

11.1.3 Roche Non-oncology Biopharmaceuticals Introduction

11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.1.5 Roche Recent Development

11.2 Sanofi

11.2.1 Sanofi Company Detail

11.2.2 Sanofi Business Overview

11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction

11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.2.5 Sanofi Recent Development

11.3 Johnson & Johnson

11.3.1 Johnson & Johnson Company Detail

11.3.2 Johnson & Johnson Business Overview

11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction

11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.3.5 Johnson & Johnson Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Detail

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction

11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.4.5 Pfizer Recent Development

11.5 Novo Nordisk

11.5.1 Novo Nordisk Company Detail

11.5.2 Novo Nordisk Business Overview

11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction

11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.5.5 Novo Nordisk Recent Development

11.6 Novartis

11.6.1 Novartis Company Detail

11.6.2 Novartis Business Overview

11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction

11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.6.5 Novartis Recent Development

11.7 Merck

11.7.1 Merck Company Detail

11.7.2 Merck Business Overview

11.7.3 Merck Non-oncology Biopharmaceuticals Introduction

11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.7.5 Merck Recent Development

11.8 Teva

11.8.1 Teva Company Detail

11.8.2 Teva Business Overview

11.8.3 Teva Non-oncology Biopharmaceuticals Introduction

11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.8.5 Teva Recent Development

11.9 Eli Lilly

11.9.1 Eli Lilly Company Detail

11.9.2 Eli Lilly Business Overview

11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction

11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.9.5 Eli Lilly Recent Development

11.10 Bristol-Myers Squibb

11.10.1 Bristol-Myers Squibb Company Detail

11.10.2 Bristol-Myers Squibb Business Overview

11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction

11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.10.5 Bristol-Myers Squibb Recent Development

11.11 GlaxoSmithKline

11.11.1 GlaxoSmithKline Company Detail

11.11.2 GlaxoSmithKline Business Overview

11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction

11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.11.5 GlaxoSmithKline Recent Development

11.12 UCB Pharma

11.12.1 UCB Pharma Company Detail

11.12.2 UCB Pharma Business Overview

11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction

11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.12.5 UCB Pharma Recent Development

11.13 Amgen

11.13.1 Amgen Company Detail

11.13.2 Amgen Business Overview

11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction

11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.13.5 Amgen Recent Development

11.14 AbbVie

11.14.1 AbbVie Company Detail

11.14.2 AbbVie Business Overview

11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction

11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.14.5 AbbVie Recent Development

11.15 Takeda

11.15.1 Takeda Company Detail

11.15.2 Takeda Business Overview

11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction

11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.15.5 Takeda Recent Development

11.16 AstraZeneca

11.16.1 AstraZeneca Company Detail

11.16.2 AstraZeneca Business Overview

11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction

11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.16.5 AstraZeneca Recent Development

11.17 Mylan

11.17.1 Mylan Company Detail

11.17.2 Mylan Business Overview

11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction

11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.17.5 Mylan Recent Development

11.18 LEO Pharma

11.18.1 LEO Pharma Company Detail

11.18.2 LEO Pharma Business Overview

11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction

11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.18.5 LEO Pharma Recent Development

11.19 Boehringer Ingelheim

11.19.1 Boehringer Ingelheim Company Detail

11.19.2 Boehringer Ingelheim Business Overview

11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction

11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.19.5 Boehringer Ingelheim Recent Development

11.20 Alexion Pharmaceuticals

11.20.1 Alexion Pharmaceuticals Company Detail

11.20.2 Alexion Pharmaceuticals Business Overview

11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction

11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.20.5 Alexion Pharmaceuticals Recent Development

11.21 Elusys Therapeutics

11.21.1 Elusys Therapeutics Company Detail

11.21.2 Elusys Therapeutics Business Overview

11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction

11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.21.5 Elusys Therapeutics Recent Development

11.22 Swedish Orphan Biovitrum

11.22.1 Swedish Orphan Biovitrum Company Detail

11.22.2 Swedish Orphan Biovitrum Business Overview

11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction

11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.22.5 Swedish Orphan Biovitrum Recent Development

11.23 Biogen

11.23.1 Biogen Company Detail

11.23.2 Biogen Business Overview

11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction

11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.23.5 Biogen Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Biologics

Table 3. Key Players of Biosimilars

Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Non-oncology Biopharmaceuticals Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2019-2024)

Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2025-2030)

Table 10. Non-oncology Biopharmaceuticals Market Trends

Table 11. Non-oncology Biopharmaceuticals Market Drivers

Table 12. Non-oncology Biopharmaceuticals Market Challenges

Table 13. Non-oncology Biopharmaceuticals Market Restraints

Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2019-2024)

Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023)

Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service

Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2019-2024)

Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2025-2030)

Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2019-2024)

Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2025-2030)

Table 31. North America Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 46. Roche Company Detail

Table 47. Roche Business Overview

Table 48. Roche Non-oncology Biopharmaceuticals Product

Table 49. Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 50. Roche Recent Development

Table 51. Sanofi Company Detail

Table 52. Sanofi Business Overview

Table 53. Sanofi Non-oncology Biopharmaceuticals Product

Table 54. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 55. Sanofi Recent Development

Table 56. Johnson & Johnson Company Detail

Table 57. Johnson & Johnson Business Overview

Table 58. Johnson & Johnson Non-oncology Biopharmaceuticals Product

Table 59. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 60. Johnson & Johnson Recent Development

Table 61. Pfizer Company Detail

Table 62. Pfizer Business Overview

Table 63. Pfizer Non-oncology Biopharmaceuticals Product

Table 64. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 65. Pfizer Recent Development

Table 66. Novo Nordisk Company Detail

Table 67. Novo Nordisk Business Overview

Table 68. Novo Nordisk Non-oncology Biopharmaceuticals Product

Table 69. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 70. Novo Nordisk Recent Development

Table 71. Novartis Company Detail

Table 72. Novartis Business Overview

Table 73. Novartis Non-oncology Biopharmaceuticals Product

Table 74. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 75. Novartis Recent Development

Table 76. Merck Company Detail

Table 77. Merck Business Overview

Table 78. Merck Non-oncology Biopharmaceuticals Product

Table 79. Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 80. Merck Recent Development

Table 81. Teva Company Detail

Table 82. Teva Business Overview

Table 83. Teva Non-oncology Biopharmaceuticals Product

Table 84. Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 85. Teva Recent Development

Table 86. Eli Lilly Company Detail

Table 87. Eli Lilly Business Overview

Table 88. Eli Lilly Non-oncology Biopharmaceuticals Product

Table 89. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 90. Eli Lilly Recent Development

Table 91. Bristol-Myers Squibb Company Detail

Table 92. Bristol-Myers Squibb Business Overview

Table 93. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product

Table 94. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 95. Bristol-Myers Squibb Recent Development

Table 96. GlaxoSmithKline Company Detail

Table 97. GlaxoSmithKline Business Overview

Table 98. GlaxoSmithKline Non-oncology Biopharmaceuticals Product

Table 99. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 100. GlaxoSmithKline Recent Development

Table 101. UCB Pharma Company Detail

Table 102. UCB Pharma Business Overview

Table 103. UCB Pharma Non-oncology Biopharmaceuticals Product

Table 104. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 105. UCB Pharma Recent Development

Table 106. Amgen Company Detail

Table 107. Amgen Business Overview

Table 108. Amgen Non-oncology Biopharmaceuticals Product

Table 109. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 110. Amgen Recent Development

Table 111. AbbVie Company Detail

Table 112. AbbVie Business Overview

Table 113. AbbVie Non-oncology Biopharmaceuticals Product

Table 114. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 115. AbbVie Recent Development

Table 116. Takeda Company Detail

Table 117. Takeda Business Overview

Table 118. Takeda Non-oncology Biopharmaceuticals Product

Table 119. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 120. Takeda Recent Development

Table 121. AstraZeneca Company Detail

Table 122. AstraZeneca Business Overview

Table 123. AstraZeneca Non-oncology Biopharmaceuticals Product

Table 124. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 125. AstraZeneca Recent Development

Table 126. Mylan Company Detail

Table 127. Mylan Business Overview

Table 128. Mylan Non-oncology Biopharmaceuticals Product

Table 129. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 130. Mylan Recent Development

Table 131. LEO Pharma Company Detail

Table 132. LEO Pharma Business Overview

Table 133. LEO Pharma Non-oncology Biopharmaceuticals Product

Table 134. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 135. LEO Pharma Recent Development

Table 136. Boehringer Ingelheim Company Detail

Table 137. Boehringer Ingelheim Business Overview

Table 138. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product

Table 139. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 140. Boehringer Ingelheim Recent Development

Table 141. Alexion Pharmaceuticals Company Detail

Table 142. Alexion Pharmaceuticals Business Overview

Table 143. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product

Table 144. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 145. Alexion Pharmaceuticals Recent Development

Table 146. Elusys Therapeutics Company Detail

Table 147. Elusys Therapeutics Business Overview

Table 148. Elusys Therapeutics Non-oncology Biopharmaceuticals Product

Table 149. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 150. Elusys Therapeutics Recent Development

Table 151. Swedish Orphan Biovitrum Company Detail

Table 152. Swedish Orphan Biovitrum Business Overview

Table 153. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product

Table 154. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 155. Swedish Orphan Biovitrum Recent Development

Table 156. Biogen Company Detail

Table 157. Biogen Business Overview

Table 158. Biogen Non-oncology Biopharmaceuticals Product

Table 159. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 160. Biogen Recent Development

Table 161. Research Programs/Design for This Report

Table 162. Key Data Information from Secondary Sources

Table 163. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Non-oncology Biopharmaceuticals Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Non-oncology Biopharmaceuticals Market Share by Type: 2023 VS 2030

Figure 3. Biologics Features

Figure 4. Biosimilars Features

Figure 5. Global Non-oncology Biopharmaceuticals Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Non-oncology Biopharmaceuticals Market Share by Application: 2023 VS 2030

Figure 7. Immunology Case Studies

Figure 8. Endocrinology Case Studies

Figure 9. Others Case Studies

Figure 10. Non-oncology Biopharmaceuticals Report Years Considered

Figure 11. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Region: 2023 VS 2030

Figure 14. Global Non-oncology Biopharmaceuticals Market Share by Players in 2023

Figure 15. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2023

Figure 17. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)

Figure 19. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)

Figure 23. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Region (2019-2030)

Figure 31. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)

Figure 39. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)

Figure 43. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 46. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 47. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 48. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 49. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 50. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 51. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 52. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 53. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 55. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 56. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 57. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 58. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 59. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 60. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 61. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 62. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 63. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 64. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 65. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 66. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 67. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Substrate Cutting Device Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-23Z18292

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Targeted Radionuclide Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-14Z15017

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global Microfluidic Single-Cell Analysis and Screening System Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-7M18883

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Medicinal Liquid Filling Equipment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37J14968

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Non-oncology Biopharmaceuticals Market Research Report 2024

Published Date: March 2024

Report Code: QYRE-Auto-4J6201

Global Non-oncology Biopharmaceuticals Market Research Report 2024

FEATURED COMPANIES

Non-oncology Biopharmaceuticals Market Size

Non-oncology Biopharmaceuticals Market

Report Scope

Scope of Non-oncology Biopharmaceuticals Market Report

Chapter Outline

FAQ for this report

How fast is Non-oncology Biopharmaceuticals Market growing?

What is the Non-oncology Biopharmaceuticals Market size in 2030?

Who are the main players in the Non-oncology Biopharmaceuticals Market report?

What are the Application segmentation covered in the Non-oncology Biopharmaceuticals Market report?

What are the Type segmentation covered in the Non-oncology Biopharmaceuticals Market report?

FEATURED COMPANIES

RELATED REPORTS